BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 17, 2008
View Archived Issues
Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial
Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today)
Read More
Mpex, GSK in Antibiotics Deal Using Efflux Pump Inhibitors
Read More
'Circuit Neuromics' Championed as Path to Understanding Mood
Read More
Want a Wicked Cool Hat? Try the BioWorld Booth
Read More
Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer
Read More
Other News To Note
Read More
EHA Roundup
Read More
Clinic Roundup
Read More
Financings Roundup
Read More